利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.015 秒)

    SKIN IMMUNIZATION USING LT-STA FUSION PROTEINS
    3.
    发明申请
    SKIN IMMUNIZATION USING LT-STA FUSION PROTEINS 审中-公开
    使用LT-STA融合蛋白进行皮肤免疫

    公开(公告)号：US20090017056A1

    公开(公告)日：2009-01-15

    申请号：US11629620

    申请日：2005-06-15

    申请人： Jian-Hui Tian ,  Gregory M. Glenn ,  Larry R. Ellingsworth

    发明人： Jian-Hui Tian ,  Gregory M. Glenn ,  Larry R. Ellingsworth

    IPC分类号： A61K39/02 ,  C07K19/00

    CPC分类号： A61K39/385 ,  A61K2039/6037 ,  A61K2039/627 ,  C07K2319/40 ,  C07K2319/55

    摘要： This invention includes fusion proteins comprising a bacterial ADP-ribosylating exotoxin (bARE), or a variant or portion thereof, fused to a STa exotoxin, or a portion or variant thereof. Optionally, the exotoxins are fused via a peptide linker. The invention also includes compositions formulated for transcutaneous immunizations and/or induction of an immune response by epicutaneous administration comprising an effective amount of a fusion protein comprising a bacterial ADP-ribosylating exotoxin fused to a STa exotoxin. Optionally, the exotoxins are fused via a peptide linker.

    摘要翻译： 本发明包括融合蛋白质，其包含与STa外毒素融合的细菌ADP-核糖基化外毒素（bARE）或其变体或部分，或其部分或变体。 任选地，外毒素通过肽接头融合。 本发明还包括配制用于经皮免疫和/或通过皮肤施用诱导免疫应答的组合物，其包含有效量的融合蛋白，所述融合蛋白包含与STa外毒素融合的细菌ADP-核糖基化外毒素。 任选地，外毒素通过肽接头融合。

    Transcutaneous immunostimulation
    4.
    发明申请
    Transcutaneous immunostimulation 审中-公开
    经皮免疫刺激

    公开(公告)号：US20090136480A1

    公开(公告)日：2009-05-28

    申请号：US11882888

    申请日：2007-08-06

    申请人： Gregory M. Glenn ,  Larry R. Ellingsworth ,  Scott A. Hammond

    发明人： Gregory M. Glenn ,  Larry R. Ellingsworth ,  Scott A. Hammond

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： A61K39/39 ,  A61K9/7061 ,  A61K2039/54 ,  A61K2039/55544

    摘要： Transcutaneous immunostimulation administers at least one adjuvant by transcutaneous immunization to a subject who has undergone, is undergoing, or will undergo conventional vaccination or another immune response. A subject is selected for treatment to stimulate the immune response to a conventional vaccine or other immuno-therapy. A suspicion, medical history, or determination by a physician or veterinarian that the subject may fail to respond or only poorly respond to conventional vaccination or other immunotherapy because of age, acquired or congenital immunodeficiency, immunosuppression caused by disease or ablative therapy, or the use of reduced amounts of antigen in the conventional vaccine can be used to select subjects in need of treatment.

    摘要翻译： 经皮免疫刺激通过经皮免疫给经历，正在接受或将要经历常规接种或其他免疫应答的受试者施用至少一种佐剂。 选择受试者用于治疗以刺激对常规疫苗或其它免疫疗法的免疫应答。 由于年龄，获得性或先天性免疫缺陷，由疾病或消融性治疗引起的免疫抑制，受试者可能无法应对或仅对常规接种疫苗或其他免疫治疗反应差或怀疑，病史或决心，或使用 可以使用常规疫苗中减少量的抗原来选择需要治疗的受试者。